Actinogen Medical Introduces Emestedastat for Xanamem
Actinogen Medical Limited (ASX: ACW) has announced a significant milestone in its Alzheimer's treatment journey with the introduction of the nonproprietary name 'emestedastat' for its leading drug, Xanamem. This recognition by the World Health Organization (WHO) places Actinogen at the forefront of clinical innovation in the fight against Alzheimer’s disease.
Understanding Emestedastat
The name 'emestedastat' aligns with the World Health Organization’s standardized naming conventions, signifying a unique class of medications known as 11?-HSD1 enzyme inhibitors. This class is pivotal in regulating cortisol, often referred to as the 'stress hormone.' In Alzheimer's patients, elevated cortisol levels are known to contribute to cognitive decline, making this therapy a critical area of exploration.
Features of Emestedastat
Emestedastat stands out as a once-a-day small molecule designed to control cortisol levels in the brain, thereby potentially alleviating the effects of conditions like Alzheimer's disease and major depressive disorder. With its first-in-class status, Xanamem is deeply intertwined with the emerging field of neuropsychiatric treatment focused on hormone regulation.
Clinical Trials Showing Promise
Current clinical trials, specifically the XanaMIA phase 2b/3 trial, are gaining momentum as numerous sites across the USA and Australia actively sponsor participant enrollment. This critical study focuses on patients diagnosed with mild to moderate Alzheimer's disease who have elevated pTau181 biomarkers, suggesting a high risk of progression during the 36-week treatment phase.
CEO's Insights on Emestedastat
Dr. Steven Gourlay, CEO and Managing Director of Actinogen, expressed enthusiasm about this recognition, stating how the new suffix in 'emestedastat' reflects the company's leadership in treating conditions linked to cortisol dysregulation in the brain. He emphasized the clinical confidence surrounding the outcomes seen in previous trials, particularly with positive impacts on patients with Alzheimer’s disease and major depressive disorder.
Preparing for Commercialization
Actinogen is actively pursuing a range of initiatives in preparation for the commercialization of Xanamem. Appointing well-respected leaders in drug development, including Chief Commercial Officer Andrew Udell, signifies strategic growth and a commitment to navigating regulatory pathways effectively, especially concerning the FDA.
Regulatory and Development Activities
Regulatory discussions are ongoing, and efforts to scale up drug substance manufacturing are underway. Actinogen is also devoted to publishing peer-reviewed manuscripts related to its clinical findings and is exploring additional nonclinical studies to ensure thorough examination of Xanamem’s efficacy as a late-stage contender in Alzheimer’s treatment.
About Actinogen Medical
Actinogen Medical (ACW) operates at the intersection of biotechnology and neuropsychiatric healthcare. The company is dedicated to developing a unique therapy to address neurological diseases linked to excessive cortisol. The direct correlation between high cortisol levels and cognitive impairment underlines the need for innovative treatment options in this arena.
Future Directions and Aspirations
With a robust development pipeline, Actinogen not only seeks advancements in Alzheimer's therapy but also aims to explore treatment possibilities for other neuropsychiatric conditions, including Fragile X Syndrome. The potential for decreasing cortisol levels in the brain could pave the way for improved health outcomes across various debilitating diseases.
Frequently Asked Questions
What is emestedastat?
Emestedastat is the new nonproprietary name for Xanamem, developed by Actinogen Medical, targeting cortisol regulation in the brain.
How does Xanamem work?
Xanamem inhibits the 11?-HSD1 enzyme to control cortisol levels in the brain, addressing cognitive decline associated with Alzheimer's disease.
What is the significance of the WHO recognition?
The WHO’s designation of emestedastat as a nonproprietary name reflects its global acknowledgment as a unique therapeutic option in Alzheimer's treatment.
What are the upcoming milestones for Actinogen?
Actinogen aims to achieve successful trial results, prepare for regulatory approvals, and advance Xanamem towards commercialization.
Can patients still join the XanaMIA trial?
Yes, patients interested in participating in the XanaMIA phase 2b/3 trial can inquire about their eligibility through Actinogen’s channels.
